Literature DB >> 8953188

High-performance liquid chromatographic assay for meropenem in serum.

H Elkhaïli1, S Niedergang, D Pompei, L Linger, D Leveque, F Jehl.   

Abstract

High-performance liquid chromatographic procedures have been developed for the measurement of meropenem in serum. The separation was performed on an Ultrasphere XL-ODS analytical column (75 x 4.6 min I.D.). The mobile phase consisted of 10.53 mmol/l ammonium acetate-acetonitrile (95:5, v/v) (pH 4). The UV detection was at 298 nm. The quantitation limit both in serum and water was 0.25 micrograms/ml. The method was validated in serum and aqueous solution over the concentration range 0.25-50 micrograms/ml. The extraction recovery from serum spiked with meropenem was 99.7 +/- 3.4%. The intra- and inter-assay coefficients of variation were below 6%. Stored at -80 degrees C for three months at various concentrations in serum and in aqueous solution, meropenem did not reveal any appreciable degradation. After 24 h, it was also stable at 4 degrees C in serum, aqueous solution and supernatant of extraction but not at room temperature. The stability of the drug was also confirmed in serum after repeated freezing-thawing cycles at -80 degrees C on four consecutive days.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8953188     DOI: 10.1016/s0378-4347(96)00205-8

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  13 in total

1.  In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.

Authors:  Dora E Wiskirchen; Pornpan Koomanachai; Anthony M Nicasio; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.

Authors:  Marguerite L Monogue; Masakatsu Tsuji; Yoshinori Yamano; Roger Echols; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

3.  Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.

Authors:  Catharine C Bulik; Henry Christensen; Peng Li; Christina A Sutherland; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

4.  Optimization of meropenem dosage in the critically ill population based on renal function.

Authors:  Jared L Crandon; Robert E Ariano; Sheryl A Zelenitsky; Anthony M Nicasio; Joseph L Kuti; David P Nicolau
Journal:  Intensive Care Med       Date:  2010-12-07       Impact factor: 17.440

5.  Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae.

Authors:  O Mimoz; S Leotard; A Jacolot; C Padoin; K Louchahi; O Petitjean; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

6.  Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).

Authors:  Eric Viaene; Hugues Chanteux; Hélène Servais; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy.

Authors:  Julia Langgartner; Antje Vasold; Thomas Glück; Michel Reng; Frieder Kees
Journal:  Intensive Care Med       Date:  2008-02-23       Impact factor: 17.440

8.  Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.

Authors:  C Andrew DeRyke; Mary Anne Banevicius; Hong Wei Fan; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

9.  In Vivo Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model.

Authors:  Kamilia Abdelraouf; Aryun Kim; Kevin M Krause; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

10.  Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.

Authors:  Emily L Heil; David P Nicolau; Andras Farkas; Jason A Roberts; Kerri A Thom
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.